Immunovant, Inc. IMVT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s investing cash flow?
- Immunovant, Inc. (IMVT) reported investing cash flow of -$8K in Q1 2026.
- How has Immunovant, Inc.'s investing cash flow changed year-over-year?
- Immunovant, Inc.'s investing cash flow increased by 96.0% year-over-year, from -$201K to -$8K.
- What is the long-term trend for Immunovant, Inc.'s investing cash flow?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s investing cash flow has grown at a -57.9% compound annual growth rate (CAGR), from -$254K to -$8K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.